Page 119 - Drug Class Review

Drug Effectiveness Review Project
Alzheimer classification: Mild-moderate
Groups similar at baseline: Yes

donepezil placebo 69.4 70.1 66 68 100 100 62%, 38% 68%, 32% 16.6 17.8 26.90 22.91 ome Measures: ADAS-J-Cog; J-CGIC Secondary Outcome Measures: CDR-SB; MENFIS; CMCS Timing of assessments: Baseline and every 4 weeks Health Outcome Measures: Significantly more improvement in CMCS for DON-treated patients (P = 0.01) at endpoint Intermediate Outcome Measures: DON was significantly better than placebo on ADAS-J-Cog (P = 0.003) and J-CGIC (P < 0.001)* Significantly more improvement in CDR-SB for DON-treated patients (P < 0.001) at endpoint Signifi

Primary Outc • • • •

Final Report Update 1 Authors: Homma et al. Year: 2000 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity (% Japanese): Other germane population qualities: CDR 1,2 • Mean baseline MMSE • Mean ADAS-J-Cog • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs